These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 25360866)

  • 21. Bioanalytical challenges of biosimilars.
    Islam R
    Bioanalysis; 2014 Feb; 6(3):349-56. PubMed ID: 24471955
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Current situations and the future prospect of monoclonal antibody products].
    Yamaguchi T
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2014; (132):36-46. PubMed ID: 25707201
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Biosimilar medicines. Scientific and legal disputes].
    Dorantes Calderón B; Montes Escalante IM
    Farm Hosp; 2010 Mar; 34 Suppl 1():29-44. PubMed ID: 20920856
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biosimilar safety considerations in clinical practice.
    Choy E; Jacobs IA
    Semin Oncol; 2014 Feb; 41 Suppl 1():S3-14. PubMed ID: 24560025
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estimation and approximation approaches for biosimilar index based on reproducibility probability.
    Yang LY; Lai CH
    J Biopharm Stat; 2014; 24(6):1298-311. PubMed ID: 25033191
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analytical and bioanalytical assay challenges to support comparability studies for biosimilar drug development.
    Cai XY; Wake A; Gouty D
    Bioanalysis; 2013 Mar; 5(5):517-20. PubMed ID: 23425265
    [No Abstract]   [Full Text] [Related]  

  • 27. Market entry of biosimilar low-molecular-weight heparins in Europe: opportunities and challenges.
    Simoens S; Huys I
    Semin Thromb Hemost; 2013 Apr; 39(3):250-7. PubMed ID: 23235959
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biosimilar insulins are coming: the top 10 things you should know.
    Blumer I; Edelman S
    Postgrad Med; 2014 May; 126(3):107-10. PubMed ID: 24918796
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Perspective on regulation of biosimilar products].
    Yamaguchi T
    Nihon Rinsho; 2012 Nov; 70 Suppl 8():678-87. PubMed ID: 23513921
    [No Abstract]   [Full Text] [Related]  

  • 30. First biosimilar drug approved in the USA.
    Burki TK
    Lancet Oncol; 2015 Apr; 16(4):e161. PubMed ID: 25773170
    [No Abstract]   [Full Text] [Related]  

  • 31. Biosimilar competition: lessons from Europe.
    Grabowski H; Guha R; Salgado M
    Nat Rev Drug Discov; 2014 Feb; 13(2):99-100. PubMed ID: 24445562
    [No Abstract]   [Full Text] [Related]  

  • 32. Biosimilar draft guidance issue by US FDA.
    Payne T
    Bioanalysis; 2012 Apr; 4(7):759. PubMed ID: 22512794
    [No Abstract]   [Full Text] [Related]  

  • 33. [Biosimilars].
    Krämer I
    Ther Umsch; 2011 Nov; 68(11):659-66. PubMed ID: 22045529
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Global regulatory standards for the approval of biosimilars.
    Mounho B; Phillips A; Holcombe K; Grampp G; Lubiniecki T; Mollerup I; Jones C
    Food Drug Law J; 2010; 65(4):819-37, ii-iii. PubMed ID: 24479248
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessing biosimilarity and interchangeability of biosimilar products.
    Chow SC
    Stat Med; 2013 Feb; 32(3):361-3. PubMed ID: 23307569
    [No Abstract]   [Full Text] [Related]  

  • 36. Encouraging guidance released for biosimilar manufacturers.
    Reinke T
    Manag Care; 2014 Aug; 23(8):10, 13. PubMed ID: 25225711
    [No Abstract]   [Full Text] [Related]  

  • 37. Pharmacovigilance and biosimilars: considerations, needs and challenges.
    Casadevall N; Edwards IR; Felix T; Graze PR; Litten JB; Strober BE; Warnock DG
    Expert Opin Biol Ther; 2013 Jul; 13(7):1039-47. PubMed ID: 23527621
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biosimilar drugs in Mexico: position of the Mexican College of Rheumatology, 2012.
    Espinosa Morales R; Díaz Borjón A; Barile Fabris LA; Esquivel Valerio JA; Medrano Ramírez G; Arce Salinas CA; Barreira Mercado ER; Cardiel Ríos MH; Díaz Jouanen E; Flores Murrieta FJ; Fraga Mouret A; Garza Elizondo MA; Luján Estrada M; Muñoz Barradas FJ; Talavera Piña JO; Vera Lastra OL;
    Reumatol Clin; 2013; 9(2):113-6. PubMed ID: 23395225
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biosimilars: the need, the challenge, the future: the FDA perspective.
    Epstein MS; Ehrenpreis ED; Kulkarni PM;
    Am J Gastroenterol; 2014 Dec; 109(12):1856-9. PubMed ID: 24957160
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biosimilar makers flout forced patent negotiations in US.
    Willyard C
    Nat Med; 2015 Feb; 21(2):100-1. PubMed ID: 25654591
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.